Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation

Background

The International Myeloma Working Group (IMWG) defines progression of disease (PD) in multiple myeloma by the increase in serum or urine paraprotein beyond a certain threshold. With more common use of serial bone marrow-based measurable residual disease (MRD) assessment, some patients will evolve with increase in MRD burden without meeting IMWG criteria for PD and no consensus exist on the best approach for this circumstance. Understanding the implication of increasing MRD burden is particularly relevant in patients with NDMM treated with quadruplet therapy (QUAD, consisting of a PI, an IMiD, an anti-CD38 mAb and dexamethasone) and autologous stem cell transplantation (ASCT), since most will reach MRD negativity.

Methods

We analyzed a large dataset of patients with NDMM patients treated with QUADs + ASCT +/- QUAD consolidation +/- single or dual-agent maintenance and monitored with serial MRD assessment by next-generation sequencing (clonoSEQ®) at end of induction, post ASCT, post consolidation and at least yearly thereafter. The dataset was built from clinical trial participants and from patients receiving standard care under an institutional guideline. MRD progression (MRD-P) was arbitrarily defined as quantitative increase in MRD burden by at least 1 log₁₀ above the nadir. Treatment modification in the event of MRD-P without IMWG-defined PD was at discretion of treating physician. For patients with MRD-P without concomitant PD we describe cumulative incidence of PD after MRD-P. To contextualize the clinical implications of MRD-P, we describe survival free of failure of second line therapy (SFF2T), defined as time from progression event (MRD-P or PD not preceded by MRD-P) until occurrence of IMWG-defined PD or death on second line therapy, regardless of whether second line was initiated due to MRD-P or subsequent IMWG-defined PD.

Results

Among the 216 patients, 113 (52%) were clinical trial participants, median age was 61 years (IQR 56-68), 21% age 70 or older, 32% were non-White, 57% male, 38% had MM with 1 high risk chromosome abnormality [HRCA, gain/amp 1q, t(4;14), t(14:16), del(17p)], 15% had 2+HRCA. Median duration of follow up is 39.5 months, and 966 MRD datapoints were assessed. Overall, 83% of patients achieved sCR, 78% achieved MRD negativity at 10^-5, 68% at the 10^-6 threshold, and 56% ceased therapy after confirmed MRD negativity. Forty-nine patients had MRD-P(N=19) or PD not preceded by MRD-P (N=30). Patients with MRD-P or PD not preceded by MRD-P often had 1 or more HRCA (73.7% and 82.8%), International staging system III (36.8% and 30.0%), and high LDH at diagnosis (31.6% and 23.3%). Median time from onset of therapy to MRD-P was 24.4 mo (IQR 12.6-35.8) and to PD not preceded by MRD-P was 23.2 mo (IQR 18.4-29.4). Among the 19 patients with MRD-P, 12 (63%) were on observation at time of MRD-P, 2 were receiving single agent lenalidomide, 5 were receiving a QUAD, 17 (89%) had previously obtained MRD negativity at <10^-5 including 10 (53%) who had also achieved MRD negativity at 10^-6. Upon detection of MRD-P, 12 (63%) pts changed therapy, all to a monoclonal antibody-containing triplet or quadruplet regimen. Yet, median time from MRD-P to PD was 10.1 months. Patients with MRD-P had 1-year SFF2T of 55.6%, in contrast to 35.0% for patients with PD not preceded by MRD-P. OS 2-year from progression event was 78.0% for MRD-P and 53.9% for PD not preceded by MRD-P.

Conclusions

In the context of NDMM treated with QUAD + ASCT, MRD-P indicates imminent IMWG-defined PD, and is driven by a thriving plasma cell population unlikely to be controlled by reinstitution of anti-CD38 mAb-based combinations. Outcomes of patients with MRD-P are similar to those of patients with IMWG-defined PD. These findings challenge the paradigm of IMWG-defined PD and paraprotein measurability as minimal parameters for change in therapy and introduction of agents with new mechanisms of action.

Costa:Caribou: Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Adaptive biotechnoligies: Honoraria; Pfizer: Consultancy, Honoraria; Genentech, Inc.: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria. Dhakal:C4 therapeutics: Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; Janssen: Honoraria, Research Funding, Speakers Bureau; Karyopharm: Honoraria, Speakers Bureau; Acrellx: Research Funding; Carsgen: Research Funding; Sanofi: Research Funding; Pfizer: Consultancy, Honoraria, Speakers Bureau; Genentech: Consultancy, Honoraria; Medical College of Wisconsin: Current Employment. Giri:Janssen Research & Development, LLC: Honoraria, Research Funding, Speakers Bureau; Sanofi: Honoraria, Research Funding, Speakers Bureau. Chhabra:Ascentage Pharma: Honoraria. Bal:Adaptive Biotechnologies: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; Janssen: Consultancy; AstraZeneca: Consultancy; MJH LifeSciences: Consultancy; Amyloid Foundation: Research Funding; BeiGene: Consultancy; Fate Therapeutics: Consultancy; AbbVie: Consultancy, Research Funding. Ravi:Guidepoint: Consultancy. Silbermann:Sanofi: Consultancy, Research Funding; Janssen Oncology: Research Funding; Pfizer: Consultancy; Oncopeptides: Consultancy.